Kornimate/medical-research-clean huggingface dataset:
povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis

Conditions: Adenoviral Keratoconjunctivitis

Summary: povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis

diagnosed ekc patients will be devided into two groups,first group will undergo povidone-iodine 2% eye drop four times a day and the control group will be treated only by artificial tear drops,they will be examined 3 months later and evaluations and data collections for the final comparison will be done.

Eligibility criteria:
inclusion criteria: * patients suspected for viral conjunctivitis exclusion criteria: * allergic to iodized materials * age under 17
postoperative prognosis management service based mhealth for colon cancer patients

Conditions: Colon Cancer

Summary: recently, the use of mobile health is increasing for the purpose of managing prognosis such as recurrence, survival and quality of life by using a wearable smart band and a smartphone application. in the era of the 4th revolution, mobile health for the purpose of comprehensive prognosis for cancer patients is becoming a very good tool. it is possible to confirm the clinical significance of short-term and temporary health care through a mobile application and a smart band during the treatment process for cancer patients, but the study is insufficient to generalize the number of subjects. therefore, for colon cancer patients who need prognosis management after surgery, we will investigate the effect of a mobile application using a smart band which has a modular structure reflecting the treatment method and treatment process after surgery. this study targets patients who underwent prostate cancer surgery. an intervention group (app+iot device) uses a smart care application for 12 months. this application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. and they also uses a wearable smart band for 12 months. control group is provided general education through the hospital brochure. evaluation will be conducted 2-3days after surgery (before discharge), and at 1, 3, 6, and 12 months after surgery.


Eligibility criteria:
inclusion criteria: * those who have been diagnosed with colorectal cancer and have undergone surgery (not related to chemotherapy treatment) * patients aged 19 to 75 years old * those who can use prognosis management applications and can perform regular follow-up inspections outpatients * patients carrying android or ios smartphones * patients who voluntarily decide to participate and give written consent after hearing detailed explanations about this study exclusion criteria: * those who are judged to be difficult to perform smartphone exercise and dietary management for colorectal cancer in general due to uncontrolled severe or underlying diseases, neuromuscular and musculoskeletal diseases * serious complications of clavein dindo classification grade 3 or higher after surgery * patients who were not discharged within 2 weeks after surgery
monıtorıng glucocortıcoıd treatment in patıents followed in rheumatology clınıc

Conditions: Glucocorticoids Toxicity; Rheumatoid Arthritis; Vasculitis; Systemic Lupus Erythematosus

Summary: hypothesis 1: a reduction in side effects is achieved with monitoring glucocorticoid treatment by using the glucocorticoid toxicity index (gti) in patients using glucocorticoids. hypothesis 2: monitoring treatment by using gti in patients using glucocorticoids causes a decrease in glucocorticoid toxicity and an increase in the quality of life of patients. hypothesis 3: with the involvement of the clinical pharmacist in the multidisciplinary team in patients using glucocorticoids, the drug-related problems of the patients are detected and prevented. the aim of this study was to evaluate the glucocorticoid treatment of patients with ra, sle and vasculitis treated with glucocorticoids prospectively by a multidisciplinary team with gti. in addition, it was aimed to identify and prevent drug-related problems by reviewing all drugs used in these patients by the clinical pharmacist.

in this study, the side effects of glucocorticoids used by patients will be evaluated using the glucocorticoid toxicity index (gti) index. this index includes areas for commonly recognized adverse events as a result of cumulative steroid exposure. it is weighted and measures both worsening and improvement. scores range from -346 to 439 with cumulative worsening score relating to an increase in gc toxicity burden. "-" points indicate improvement, "+" points indicate worsening. the higher the patient's burden of glucocorticoid toxicity, the higher his score.

Eligibility criteria:
inclusion criteria: * 18 years and over * individuals who have received glucocorticoid treatment for ra, sle or vasculitis in the last 2 years or at current admission. * patients approved by the physician to participate in the study * patients giving written consent exclusion criteria: * younger than 18 * patients with communication disabilities * patients involved in another clinical and/or drug trial

Keywords: glucocorticoid toxicity index drug-related problem glucocorticoid rheumatoid arthritis vasculitis clinical pharmacist
effectiveness of sodium hyaluronate in relieving nasal symptoms of children with seasonal allergic rhinitis

Conditions: Seasonal Allergic Rhinitis

Summary: nasal irrigation (ni) is recommended as an add-on therapy in patients with allergic rhinitis (ar). the primary purpose of this study was to evaluate the clinical effectiveness of adding hyaluronic acid (ha) solution and normal saline (nss) to nasal steroid (ns) therapy as add - on therapy in improving quality of life and reducing nasal symptom scores of children with seasonal ar (sar) with regards to ns therapy. our secondary purpose was to demonstrate the effects on eosinophil count in nasal cytology (nec), nasal airflow (naf), and resistance (nar).


Eligibility criteria:
inclusion criteria: * pediatric patients between 6 to 12-year-old; * children must have a clinical history concordant to seasonal allergic rhinitis of the previous year; * children must have skin prick test (spt) positivity to pollen (tree, grass, or weed) (positive spt is defined as; skin reaction with within 15 minutes after the test and 3 mm larger swelling compared to the negative control test; alk, hørsholm, denmark) * children must have a total nasal symptom score (tnss) of 4 or more on 4 of 7 days during the run-in period. exclusion criteria: * children who were treated with systemic/topical nasal corticosteroids, antihistamines or antibiotics, leukotriene receptor antagonists 4 weeks before the examination, * those who had upper or lower respiratory tract infections; * recipients of recent or ongoing allergen immunotherapy; * active smokers; * those with cystic fibrosis, immunodeficiency, septal deviation, nasal polyps, and ostio-metal complex, exudation, abnormal nasal diagnostic function, nasal anatomical disorder, metabolic disease, or congenital disease. * phone calls will measure children's adherence rate to treatment protocols, and participants determined to have treatment protocol adherence rates below 85% will be excluded.
a clinical study to assess the effect of vildagliptin on beta cell function in drug naive patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study is not being conducted in the united states. the purpose of this study is to assess the effect of vildagliptin, an unapproved drug, on various measures of pancreatic islet function in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.


Eligibility criteria:
inclusion criteria: * not currently on drug therapy for type 2 diabetes * blood glucose criteria must be met exclusion criteria: * history of type 1 diabetes * evidence of significant diabetic complications * serious cardiovascular events within the past 6 months * other protocol-defined exclusion criteria may apply

Keywords: type 2 diabetes vildagliptin
determining accuracy and trending characterization of af

Conditions: Atrial Fibrillation

Summary: the objective of this study is to assess the atrial fibrillation (af) episode detection when using the sjm(st. jude medical) confirm icm (implantable cardiac monitor).


Eligibility criteria:
inclusion criteria: * the subject has been implanted with a sjm confirm icm, dm2102. * the subject has or is suspected to have paroxysmal af. * the subject is ≥ 18 years of age. * the subject is willing and able to provide written informed consent (prior to any investigational related procedure). exclusion criteria: * the subject has persistent (\>7 days and ≤1 year or requiring cardioversion), longstanding persistent (continuous af \>1 year) or permanent af (not attempting to restore sinus rhythm). * the subject has af of reversible etiology (e.g. electrolyte imbalance, thyroid disease). * the subject has a contraindication to holter recording. * the subject has already received an active implantable medical device other than the sjm confirm icm, dm2102. * the subject is unable to comply with the follow up schedule. * the subject is participating in another investigational device or drug investigation. * the subject is pregnant or is planning to become pregnant during the duration of the investigation.
emovi 3d knee assessment device intervention for operational readiness

Conditions: Patellofemoral Pain; Patellofemoral Pain Syndrome

Summary: this is a randomized clinical trial investigating the use of the emovi knee kinesiography information in the treatment of anterior knee pain in physical therapy.

the purpose of this study is to assess the effectiveness of using a 3d medical assessment device versus usual care to help guide clinical decisions about the management of pfp. the objective is to determine if gathering objective biomechanical data from a three-dimensional (3d) motion capture device leads to more precise and optimal care, ultimately improving physical function and other outcomes compared to participants who receive routine care that is not guided by information from this device. participants will be recruited from primary care and physical therapy clinics at participating sites. authorized study personnel will search electronic medical records (genesis) to identify potential study participants diagnosed with knee pain. after consent and enrollment, participants will complete baseline measures and then receive a knee kinesiography exam. the participant will be entered into the kneekg system using a unique participant identifier. after the knee kinesiography exam with the kneekg, participants will be randomized 1:1 into one of two different treatment arms: 1) kneekg informed care or 2) usual care without any information from the kneekg. knee mechanics during gait is assessed with a knee kinesiography exam. the participant will walk for 5 minutes on a commercial treadmill at their comfortable speed. three-dimensional (3d) knee kinematics are captured on each leg using the kneekg system (emovi, canada). with this validated fda cleared medical device, there is an accurate quantification of specific knee biomechanical markers during gait in a clinical setting. there will be two 45-second trials to electronically capture the data which is immediately accessible through automatic reports. biomechanical markers captured include but are not limited to varus/valgus alignment at stance, varus/valgus alignment at heel strike, knee flexion angle at heel strike, total knee excursion in sagittal plane, tibial rotation at heel strike and throughout gait cycle. the entire procedure will take approximately 15-20 minutes. this procedure will occur at baseline and also again at 12 weeks.

Eligibility criteria:
inclusion criteria: * age 18-50 * active duty service member stationed at fort liberty and schofield barracks * diagnosis of patellofemoral pain (icd-10 codes: m25.2 (pain in unspecified knee), m25.561 (pain in right knee), and m25.562 (pain in left knee) exclusion criteria: * pregnancy * known to be leaving that duty station within next 3 months * concurrent lower limb injuries (examples include but are not limited to ankle sprain or hs strain) * previous knee surgery * history of traumatic knee injury, such as a ligament tear or meniscal tear * presence of rheumatoid or neurological disease

Keywords: patellofemoral pain patellofemoral pain syndrome
effects of foam roller versus kt tape on delayed onset muscle soreness

Conditions: Delayed Onset Muscle Soreness

Summary: objective of this study is to compare the effects of foam roller with kt tape on doms. the university going students will be divided in two groups, with one group receiving kinesio tape as intervention and other foam rolling as intervention. pain and range of motion will be assessed before and after the intervention and the effects of both interventions will be compared.

delayed onset muscle soreness (doms) is a common phenomenon experienced after unaccustomed or intense physical activity, characterized by muscle discomfort, pain, and reduced range of motion. various interventions have been conducted to alleviate doms symptoms, including the use of foam rollers and kinesiology tape (kt tape). this randomized controlled clinical trial aims to compare the effects of foam roller and kt tape interventions on reducing doms and improving muscle recovery. the participants would go for a single session of high intensity interval training (hiit) to induce doms. group-a participants would receive kt taping afterwards, while group-b participants would receive foam rolling as intervention. their effect would be measured using visual analog scale (vas), tenderness grading scale, knee range of motion (rom) and vertical jump height. this study delves into the applications and potential benefits of kt tape and foam roller in managing doms, shedding light on their effectiveness and how they can contribute to enhancing post-exercise recuperation and overall well-being.

Eligibility criteria:
inclusion criteria: * individuals with normal bmi (18.5 to 25 kg/m2) exclusion criteria: * individuals with history of metabolic or musculoskeletal disease. * individuals with any recent acute injury. * athletes exercising regularly and regular gymnasium going individuals.

Keywords: doms foam rolling hiit kinesio taping resistance training
adjuvant dual anti-her2 therapy in patients with small, node-negative, her2-positive breast cancer

Conditions: HER2-positive Breast Cancer

Summary: this phase ii trial aims to study the efficacy and safety of adjuvant pyrotinib plus trastuzumab in patients with tumors \<8mm, node-negative, her2-positive breast cancer.


Eligibility criteria:
inclusion criteria: 1. women aged 18-70 years old 2. have finished radical operation 3. histologically confirmed invasive ductal carcinoma (idca) 4. according to ajcc ,pt\<8mm, pn0, no evidence for metastasis 5. operation specimens are available for er, progesterone receptor (pr) and her2 detection, patients should be her2 positive tumor (ihc staining of 3+ \[uniform, intense membrane staining of \>30% of invasive tumor cells\], or a fish result of .6 her2 gene copies per nucleus or a fish ratio \[her2 gene signals to chromosome 17 signals\] of \>2.2), nuclear grade 3. 6. should have tumor tissue available and sufficient for multi-spots sampling. 7. it has been \<84 days since the date of definitive surgery, and there is adequate wound healing as determined by the treating physician. 8. has eastern cooperative oncology group (ecog) performance score 0-1, expected survival time \> 12 months 9. cardiac function had to be within normal limits (left ventricular ejection fraction \[lvef\] ≥50%), as established by multiple gated acquisition scan or echocardiography. 10. adequate bone marrow function, adequate liver and renal function, and adequate coagulation function. 11. women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable and effective method of contraception to avoid pregnancy during the study. 12. written informed consent according to the local ethics committee requirements. exclusion criteria: 1. pt≥8mm or node positive 2. metastatic breast cancer 3. any prior systemic or loco-regional treatment of breast cancer, including chemotherapy in 28 days 4. with a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma 5. patients with medical conditions that indicate intolerant to adjuvant target therapy and related treatment, including severe infection, coagulation disorder, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease 6. has symptomatic peripheral neuropathy \> grade 2 according to nci 7. known severe allergy to any drugs in this study 8. has cardiac dysfunction or lung dysfunction defined as follows: * grade ≥3 chf according to nci ctcae v 5.0 or nyha≥ii * angina which requires drug control, cardiac infraction, and any other vascular disease with apparent clinical symptoms * uncontrolled high-risk arrhythmia * uncontrolled hypertension 9. has active hepatitis b or hepatitis c with abnormal liver function tests (lfts) or is known to be hiv positive 10. patient is pregnant or breast feeding
efficacy study of rx-10100 to treat erectile dysfunction (ed)

Conditions: Erectile Dysfunction (ED)

Summary: the primary objective of this phase iia trial is to determine the effective doses and treatment period for an upcoming rx-10100 phase iib trial in subjects with erectile dysfunction (ed). the secondary objectives of this trial are to evaluate the safety and the quality of life in subjects with ed receiving rx-10100 treatment.


Eligibility criteria:
inclusion criteria: * have had ed for at least six months * stable, heterosexual relationship for at least 3 months * make at least one attempt of sexual intercourse per week during the untreated, 2-week screening period * at least 50% of attempts of sexual intercourse during the untreated baseline period must be unsuccessful * 'moderate' or 'mild to moderate' ed, defined as an iief-ef domain score between 11 and 21 measured exclusion criteria: * following previous or current medical conditions * any unstable medical, psychiatric, or substance abuse disorder * penile anatomical abnormalities * primary hypoactive sexual desire * spinal cord injury * hypogonadism * surgical prostatectomy * stable or unstable angina pectoris * myocardial infarction, stroke, or life-threatening arrhythmia * uncontrolled atrial fibrillation/flutter at screening * severe chronic or acute liver disease * moderate or severe hepatic impairment * clinically significant chronic hematological disease * bleeding disorder * significant active peptic ulcer disease * resting hypotension or hypertension * malignancy (cancers) * nyha class ii to iv heart failures * positive test for hepatitis b surface antigen (hbsag) or hepatitis c * symptomatic postural hypotension * following concomitant medication * androgens or estrogens * anti-androgens * potent inhibitors of cytochrome p450 3a4 * any other investigational drug within 30 days before visit 1 * any treatment for ed within 7 days before visit 1 or during the study * antibiotics in the penicillin class * following abnormal laboratory values * serum total testosterone level (at least 25% lower) * serum creatinine (\> 3.0 mg/dl) * elevation of ast and/or alt (\> 3 times the upper limit of normal) * diabetic subjects with an hbalc (\> 6.5%) * subjects with known hypersensitivity to amoxicillin * subjects with a history of unresponsiveness to any pde5 inhibitor treatment or a history of significant side effects leading to its treatment discontinuation

Keywords: erectile dysfunctions ed
a non-interventional study of clinical characteristics and mortality of us patients with fibrodysplasia ossificans progressiva (fop)

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)

Summary: primary objective(s): * to describe the demographic characteristics of people living with fop * to describe the prevalence of clinical characteristics of interest in people living with fop * to describe the use of key medications in people living with fop * to estimate the crude mortality rate among people with fop


Eligibility criteria:
inclusion criteria: 1. confirmed fop diagnosis 2. members from the international fibrodysplasia ossificans progressiva association (ifopa) cohort who have opted-in to be tokenized by health verity marketplace 3. must be enrolled in the closed medical claims data source for any duration of time between january 1, 2018 and december 31, 2022 exclusion criteria: 1. failure to meet inclusion criteria

Keywords: genetic disease heterotopic ossification (ho) skeletal dysplasia activin a receptor, type i (acvr1)
registry of pulmonary arterial hypertension associated with connective tissue diseases (reconnective)

Conditions: Pulmonary Arterial Hypertension; Connective Tissue Diseases

Summary: the reconnective registry is an observational single center study, focused on the subgroup of precapillary pulmonary hypertension related to connective tissue diseases. all patients will have hemodynamic confirmation by right heart catheterization and will be follow-up for at least 5 years from admission. all patients diagnosed with group i pulmonary arterial hypertension (pah) associated with connective tissue diseases (ctd) and group iv pulmonary hypertension (ph) with ctd will be included. the purpose of the registry is to learn and understand the clinical outcomes and natural history of the pulmonary arterial hypertension in this subgroup of patients to improve the medical care and treatment.

connective tissue diseases represents an important risk factor for pulmonary hypertension, either due to vasculopathy or chronic pulmonary thromboembolism. these chronic conditions are characterized by being disabling, progressive and fatal in a short time and are caused by multiple mechanisms that results in remodeling of the pulmonary microvasculature and right heart failure. in recent years, due to international registries, we have acquired a better understanding of high-risk subpopulations, their poor prognostic factors, and the results of specific combination therapies. in mexico, the national institute of medical sciences and nutrition salvador zubirán (incmnsz) is a referral center for connective tissue diseases and pathologies of the pulmonary circulation. the reconnective registry is a five years follow-up cohort that offers the possibility to obtain data regarding to the clinical characteristics and hemodynamic assesment of pulmonary circulation. the main objective is to evaluate the clinical course of the pah in this subgroup of patients and their specific therapy for pah.

Eligibility criteria:
inclusion criteria: * incident and prevalent patients diagnosed with group i associated with connective tissue diseases (ctd) * incident and prevalent patients diagnosed with group iv pulmonary arterial hypertension (pah) associated with connective tissue diseases (ctd) with evidence of a chronic thromboembolic pulmonary disease by ventilation/perfusion pulmonary gammagraph or computed tomography pulmonary angiogram with at least three months of total anticoagulation therapy. * patient diagnosed with a connective tissue disease according to the classification criteria of the american college of rheumatology. * precapillary pulmonary hypertension confirmed by right heart catheterization (rhc): mean pulmonary arterial pressure (mpap) \>20 mm hg with a pulmonary arterial wedge pressure ≤ 15 mm hg and pulmonary vascular resistance (pvr) ≥ 2.0 wood units exclusion criteria: * patients who meet the criteria for another group of pulmonary hypertension (groups ii, iii or v).

Keywords: pulmonary arterial hypertension connective tissue disease